APA (7th ed.) Citation

CP, K., KA, C., S, R., ER, B., RD, K., EA, B., . . . JD, W. (2021). Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer. Oncogene, 40(1), 189. https://doi.org/10.1038/s41388-020-01515-5

Chicago Style (17th ed.) Citation

CP, Kung, et al. "Evaluating the Therapeutic Potential of ADAR1 Inhibition for Triple-negative Breast Cancer." Oncogene 40, no. 1 (2021): 189. https://doi.org/10.1038/s41388-020-01515-5.

MLA (9th ed.) Citation

CP, Kung, et al. "Evaluating the Therapeutic Potential of ADAR1 Inhibition for Triple-negative Breast Cancer." Oncogene, vol. 40, no. 1, 2021, p. 189, https://doi.org/10.1038/s41388-020-01515-5.